Gil D. Rabinovici

52.1k total citations · 16 hit papers
316 papers, 18.4k citations indexed

About

Gil D. Rabinovici is a scholar working on Psychiatry and Mental health, Physiology and Cognitive Neuroscience. According to data from OpenAlex, Gil D. Rabinovici has authored 316 papers receiving a total of 18.4k indexed citations (citations by other indexed papers that have themselves been cited), including 188 papers in Psychiatry and Mental health, 162 papers in Physiology and 92 papers in Cognitive Neuroscience. Recurrent topics in Gil D. Rabinovici's work include Dementia and Cognitive Impairment Research (178 papers), Alzheimer's disease research and treatments (157 papers) and Functional Brain Connectivity Studies (68 papers). Gil D. Rabinovici is often cited by papers focused on Dementia and Cognitive Impairment Research (178 papers), Alzheimer's disease research and treatments (157 papers) and Functional Brain Connectivity Studies (68 papers). Gil D. Rabinovici collaborates with scholars based in United States, Sweden and Netherlands. Gil D. Rabinovici's co-authors include Bruce L. Miller, William J. Jagust, Suzanne L. Baker, William W. Seeley, Joel H. Kramer, Maria Luisa Gorno‐Tempini, Renaud La Joie, Howard J. Rosen, James P. O’Neil and Michael W. Weiner and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Gil D. Rabinovici

296 papers receiving 18.1k citations

Hit Papers

PET Imaging of Tau Deposition in the Aging Human... 2008 2026 2014 2020 2016 2016 2010 2021 2008 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PET Imaging of Tau Deposition in the Aging Human Brain
    2016 790 citations Michael Schöll, Rik Ossenkoppele et al. profile →
  2. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
    2016 779 citations Rik Ossenkoppele, Michael Schöll et al. Brain profile →
  3. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer’s disease
    2010 771 citations Gil D. Rabinovici, Joel H. Kramer et al. Brain profile →
  4. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
    2021 598 citations Bruno Dubois, Nicolas Villain et al. The Lancet Neurology profile →
  5. Episodic memory loss is related to hippocampal-mediated  -amyloid deposition in elderly subjects
    2008 546 citations Elizabeth C. Mormino, Cindee Madison et al. Brain profile →
  6. Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease
    2013 511 citations Keith Vossel, Alexander J. Beagle et al. JAMA Neurology profile →
  7. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease
    2017 475 citations Alexandre Bejanin, Renaud La Joie et al. Brain profile →
  8. New insights into atypical Alzheimer's disease in the era of biomarkers
    2021 401 citations Liana G. Apostolova, María C. Carrillo et al. The Lancet Neurology profile →
  9. Four distinct trajectories of tau deposition identified in Alzheimer’s disease
    2021 400 citations Jacob W. Vogel, Alexandra L. Young et al. Nature Medicine profile →
  10. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
    2019 369 citations Gil D. Rabinovici, Orit H. Lesman‐Segev et al. profile →
  11. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
    2022 307 citations Oskar Hansson, Adam L. Boxer et al. Alzheimer s & Dementia profile →
  12. Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
    2020 217 citations Niklas Mattsson, Shorena Janelidze et al. profile →
  13. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease
    2021 154 citations Salvatore Spina, Renaud La Joie et al. Brain profile →
  14. Aducanumab: Appropriate Use Recommendations Update
    2022 126 citations Jeffrey L. Cummings, Gil D. Rabinovici et al. profile →
  15. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review
    2022 119 citations Leonardo Iaccarino, David N. Soleimani‐Meigooni et al. Journal of Nuclear Medicine profile →
  16. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
    2025 29 citations Gil D. Rabinovici, David S. Knopman et al. Alzheimer s & Dementia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gil D. Rabinovici United States 69 9.9k 9.4k 6.1k 3.1k 3.0k 316 18.4k
Prashanthi Vemuri United States 76 10.8k 1.1× 12.0k 1.3× 6.8k 1.1× 2.4k 0.8× 4.3k 1.4× 336 22.1k
Matthew L. Senjem United States 79 10.5k 1.1× 10.5k 1.1× 6.9k 1.1× 4.1k 1.3× 4.9k 1.7× 321 20.4k
Christopher C. Rowe Australia 73 11.8k 1.2× 10.1k 1.1× 4.0k 0.7× 2.9k 0.9× 3.8k 1.3× 439 21.6k
Stephen D. Weigand United States 81 12.3k 1.2× 12.0k 1.3× 6.1k 1.0× 5.0k 1.6× 4.7k 1.6× 220 24.7k
Stefan Teipel Germany 72 6.8k 0.7× 7.3k 0.8× 5.7k 0.9× 1.8k 0.6× 3.8k 1.3× 441 17.1k
Keith A. Johnson United States 78 12.3k 1.2× 13.2k 1.4× 9.8k 1.6× 3.2k 1.0× 4.6k 1.6× 419 26.1k
Bill Thies United States 6 11.8k 1.2× 16.2k 1.7× 6.9k 1.1× 2.5k 0.8× 2.9k 1.0× 7 26.7k
Tammie L.S. Benzinger United States 61 7.5k 0.8× 6.0k 0.6× 4.1k 0.7× 1.5k 0.5× 3.3k 1.1× 397 16.4k
Kejal Kantarci United States 71 7.5k 0.8× 7.3k 0.8× 4.4k 0.7× 3.1k 1.0× 4.7k 1.6× 300 16.4k
Jonathan M. Schott United Kingdom 64 6.5k 0.6× 5.7k 0.6× 3.4k 0.6× 5.2k 1.7× 2.2k 0.8× 315 17.7k

Countries citing papers authored by Gil D. Rabinovici

Since Specialization
Citations

This map shows the geographic impact of Gil D. Rabinovici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gil D. Rabinovici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gil D. Rabinovici more than expected).

Fields of papers citing papers by Gil D. Rabinovici

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gil D. Rabinovici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gil D. Rabinovici. The network helps show where Gil D. Rabinovici may publish in the future.

Co-authorship network of co-authors of Gil D. Rabinovici

This figure shows the co-authorship network connecting the top 25 collaborators of Gil D. Rabinovici. A scholar is included among the top collaborators of Gil D. Rabinovici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gil D. Rabinovici. Gil D. Rabinovici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ranasinghe, Kamalini G., Kiwamu Kudo, Joel H. Kramer, et al.. (2025). Distinct manifestations of excitatory-inhibitory imbalance associated with amyloid-β and tau in patients with Alzheimer’s disease. Nature Communications. 16(1). 7957–7957. 2 indexed citations
2.
Brown, Jesse A., Lorenzo Pasquini, Adam M. Staffaroni, et al.. (2025). Functional network collapse in neurodegenerative disease. Nature Communications. 16(1). 10273–10273.
3.
Saloner, Rowan, Kaitlin B. Casaletto, Sruti Rayaprolu, et al.. (2025). Interrogating the plasma proteome of repetitive head impact exposure and chronic traumatic encephalopathy. Molecular Neurodegeneration. 20(1). 71–71.
4.
Rabinovici, Gil D., David S. Knopman, Javier Arbizu, et al.. (2025). Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Journal of Nuclear Medicine. 66(Supplement 2). S5–S31. 10 indexed citations
5.
Leuzy, Antoine, Ariane Bollack, Daniela Pellegrino, et al.. (2025). Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease. Alzheimer s & Dementia. 21(3). e14528–e14528. 9 indexed citations
6.
Ashford, Miriam T., Chengshi Jin, Robert Turner, et al.. (2023). Brain Health Registry Study Partner Portal: Novel infrastructure for digital, dyadic data collection. Alzheimer s & Dementia. 20(2). 846–857. 5 indexed citations
7.
Hammers, Dustin B., Liana G. Apostolova, Joel H. Kramer, et al.. (2023). Influence of amyloid and diagnostic syndrome on non‐traditional memory scores in early‐onset Alzheimer’s disease. Alzheimer s & Dementia. 19(S24). 1 indexed citations
8.
Leuzy, Antoine, Niklas Mattsson, Nicholas Cullen, et al.. (2023). Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes. Alzheimer s & Dementia. 19(7). 2994–3004. 16 indexed citations
9.
Vogel, Jacob W., Alexandra L. Young, Neil P. Oxtoby, et al.. (2021). Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nature Medicine. 27(5). 871–881. 400 indexed citations breakdown →
10.
Montembeault, Maxime, Christophe Bedetti, Ariane E. Welch, et al.. (2021). Connected speech markers of amyloid burden in primary progressive aphasia. Cortex. 145. 160–168. 7 indexed citations
11.
Strom, Amelia, Leonardo Iaccarino, Lauren Edwards, et al.. (2021). Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer’s disease. Brain. 145(2). 713–728. 56 indexed citations
12.
Dubois, Bruno, Nicolas Villain, Giovanni B. Frisoni, et al.. (2021). Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. The Lancet Neurology. 20(6). 484–496. 598 indexed citations breakdown →
13.
Asken, Breton M., William G. Mantyh, Renaud La Joie, et al.. (2021). Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults. Brain Imaging and Behavior. 15(5). 2417–2425. 14 indexed citations
14.
Spina, Salvatore, Renaud La Joie, Cathrine Petersen, et al.. (2021). Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease. Brain. 144(7). 2186–2198. 154 indexed citations breakdown →
15.
Elahi, Fanny M., Daniel J. Bennett, Samantha Walters, et al.. (2021). Retinal imaging demonstrates reduced capillary density in clinically unimpaired APOE ε4 gene carriers. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 13(1). e12181–e12181. 20 indexed citations
16.
Groot, Colin, B.T. Thomas Yeo, Jacob W. Vogel, et al.. (2020). Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology. 95(12). e1672–e1685. 21 indexed citations
17.
Ranasinghe, Kamalini G., Jungho Cha, Leonardo Iaccarino, et al.. (2020). Neurophysiological signatures in Alzheimer’s disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline. Science Translational Medicine. 12(534). 69 indexed citations
18.
Ossenkoppele, Rik, Chul Hyoung Lyoo, Carole H. Sudre, et al.. (2019). Distinct tau PET patterns in atrophy‐defined subtypes of Alzheimer's disease. Alzheimer s & Dementia. 16(2). 335–344. 77 indexed citations
19.
Laforce, Robert, Duygu Tosun, Pia Ghosh, et al.. (2014). Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. NeuroImage Clinical. 4. 508–516. 53 indexed citations
20.
Vossel, Keith, Alexander J. Beagle, Gil D. Rabinovici, et al.. (2013). Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease. JAMA Neurology. 70(9). 1158–1158. 511 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Prashanthi Vemuri Breakdown of academic impact, for papers by Matthew L. Senjem Breakdown of academic impact, for papers by Christopher C. Rowe Breakdown of academic impact, for papers by Stephen D. Weigand Breakdown of academic impact, for papers by Stefan Teipel Breakdown of academic impact, for papers by Keith A. Johnson Breakdown of academic impact, for papers by Bill Thies Breakdown of academic impact, for papers by Tammie L.S. Benzinger Breakdown of academic impact, for papers by Kejal Kantarci Breakdown of academic impact, for papers by Jonathan M. Schott
Rankless by CCL
2026